Navigation Links
ChemoCentryx Announces Pricing of Initial Public Offering
Date:2/8/2012

hemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
2. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
3. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
4. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
5. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
11. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... Sept. 8 FluoroPharma, Inc. announced today ... Scientific Advisor,will report on two preclinical studies ... (PET) molecular imaging agents for detection,of Alzheimer,s ... World Molecular,Imaging Congress, in Nice, France on ...
... PRINCETON, N.J., Sept. 8 Medarex, Inc.,(Nasdaq: ... milestone payment for an,undisclosed amount from its licensing ... is a result of the submission of an ... clinical development of an antibody,generated by Medarex,s UltiMAb(R) ...
Cached Medicine Technology:FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 2Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 3
(Date:7/28/2014)... Philadelphia, PA (PRWEB) July 28, 2014 ... die each year from metastatic breast and prostate cancers ... when the cancer has spread to other parts of ... brain. Now researchers at Drexel University College of ... target they identified that inhibits metastatic progression by blocking ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... it takes humans just milliseconds to look at someone,s face ... new study finds that certain facial features seem to trigger ... shape and size of the mouth, for example, appear directly ... keys to attractiveness. The study findings suggest that ...
(Date:7/28/2014)... of a surgical procedure to treat severe chronic migraine ... percent of the time in patients treated at Massachusetts ... of Plastic and Reconstructive Surgery report that more than ... all of whom had headaches associated with compression ... year later. The team,s paper has received advance ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Thousands of ... on behalf of individuals who were allegedly injured by ... continue to move forward in U.S. District Court, Northern ... an Order issued on July 18, 2014, U.S. District ... filed by the Plaintiffs’ Steering Committee that sought the ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... SAN DIEGO, Sept. 14 Amylin Pharmaceuticals,Inc. (Nasdaq: ... at,an investor reception during the 43rd Annual Meeting of ... Wednesday, September 19,2007 at 4:30 a.m. PT / 1:30 ... live presentation will be webcast, and recordings will be ...
... BIRMINGHAM, Ala., Sept. 14 /PRNewswire-USNewswire/,-- ProAssurance Group ... a specialized,professional liability program designed for Michigan,s ... through Physicians Insurance Company,of Wisconsin, Inc. (PIC ... pleased to have the opportunity to serve ...
... product dissolves naturally , THURSDAY, Sept. 13 (HealthDay News) -- ... someone else,s used-up chewing gum. , But relief may be ... non -stick, easy-to-remove version of chewing gum at the BA ... be easily removed from shoes, clothes, hair and sidewalks, and ...
... Sept. 14 Michael Bond has,been named the ... following nearly 30 years in various roles for ... Blade Process,Engineering. Bond has a wealth of experience ... leading edge technologies for,IncisionTech and Specialty Blades. ...
... Stryker,Corporation (NYSE: SYK ) announced today that ... 25, 2007 - 4:30 p.m. Eastern Time UBS ... A simultaneous webcast of the Company,s presentation will ... the For Investors page. The,presentation for the UBS conference ...
... Most people looking for tax advice,usually go to an ... Here,s more on a new report that shows a ... actually not seeing the pros,trained in their field. ... Registered journalists can access video, audio, text, graphics ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: